TrialDrugs in R&D2018

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers.

Marie Cullberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.